Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Citizens Jmp

Analysts at Citizens Jmp assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The firm set a “market outperform” rating and a $10.00 price target on the stock. Citizens Jmp’s price objective indicates a potential upside of 80.51% from the stock’s current price.

CMPX has been the topic of a number of other research reports. Leerink Partnrs upgraded Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Lifesci Capital assumed coverage on Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective on the stock. Canaccord Genuity Group began coverage on Compass Therapeutics in a research report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Trading Up 4.9%

NASDAQ:CMPX opened at $5.54 on Wednesday. The company has a market capitalization of $985.34 million, a P/E ratio of -12.31 and a beta of 1.44. The firm has a 50-day moving average price of $4.37 and a two-hundred day moving average price of $3.39. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. On average, equities research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Creative Planning acquired a new position in shares of Compass Therapeutics in the 2nd quarter valued at $30,000. Strs Ohio purchased a new stake in shares of Compass Therapeutics during the 1st quarter valued at $34,000. Apollon Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $35,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth $37,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.